11 médicaments cherchent l'approbation de la FDA en 2012

Affymax AFFY Drug/indication:peginesatide for anemia in kidney dialysis patients. FDA advisory panel: Dec. 7, 2011 Approval decision date:March 27, 2012

Pfizer PFE Drug/indication:Inlyta (axitinib) for kidney cancer FDA advisory panel: Dec. 7, 2011 Approval decision date: Feb-April 2012

Alexza Pharmaceuticals ALXA Drug/indication:Adasuve for agitation related to schizophrenia FDA advisory panel: Dec. 12, 2011 Approval decision date: Feb. 4, 2012

Vivus VVUS , Arena Pharmaceuticals ARNA and Orexigen Therapeutics OREX Drugs/indication: Qnexa, lorcaserin and Contrave for obesit

FDA advisory panel: First quarter 2012

Columbia Labs CBRX and Watson Pharmaceuticals WPI Drug/indication:progesterone vaginal gel for risk reduction of preterm birth. FDA advisory panel: Jan. 20, 2012

Amylin Pharmaceuticals AMLN Drug/indication: Bydureon for diabetes Approval decision date: Jan. 27, 2012

Teva TEVA and BioSante Pharmaceuticals BPAX Drug/indication: Bio-T-Gel for hypogonadism Approval decision date: Feb. 14, 2012

Corcept Pharmaceuticals CORT Drug/indication: Corlux for Cushing's Syndrome. Approval decision date: Feb. 17, 2012

Discovery Labs DSCO Drug/indication: Surfaxin for respiratory distress syndrome in premature infants. Approval decision date: March 6, 2012

MAP Pharmaceuticals MAPP Drug/indication: Levadex for migraines Approval decision date: March 26, 2012

Ironwood Pharmaceuticals IRWD Drug/indication: linaclotide for irritable bowel syndrome. Approval decision date: June 8, 2012